Brighter has announced its annual report for 2015. Brighter develops solutions for data-driven and mobile healthcare. Through its intellectual capital and its innovative aids, jDome® and Actiste®, the company creates a more efficient care chain with the individual in focus.
Livongo, the mobile-enabled diabetes management company, has raised a strategic investment from Humana to support the company’s growth. Update: Humana invested $5 million in Livongo.
Senseonics, a Germantown, Maryland-based company working on a longterm implantable continuous glucose monitor, has received a CE Mark for its Eversense Continuous Glucose Monitoring (CGM) System.
#cgm
Medtronic announced that it will work with Qualcomm Life to develop a new generation of smaller, affordable continuous glucose monitors (CGMs) for people with Type 2 diabetes, the companies announced today. Currently, CGM devices are mostly prescribed for people with Type 1 diabetes, while those with Type 2 are more likely to use discrete finger-prick glucometers. However, this new partnership aims to leverage Qualcomm's expertise to develop CGMs that are smaller, easier to use, and more affordable than currently available CGMs -- in the hopes of making the technology available to those with Type 2 diabetes, an addressable market more than 20 times larger.
#product & service
#cgm
The aim of this study was to investigate stages of change for physical activity and dietary habits using baseline data from persons with type 2 diabetes included in a mobile health intervention. The associations between stages of change for physical activity change and dietary change, and between stages of change for each behavior and individual characteristics, health-related quality of life, self-management, depressive symptoms, and lifestyle were examined.
#mobile app
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System (OmniPod System), today reaffirmed its second quarter and full year 2016 guidance. A recent preferred provider communication by UnitedHealthcare regarding in-network DME insulin pumps is not expected to have a material impact on OmniPod System coverage nor on Insulet's financial results.
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim®, t:slim G4™ and t:flex® Insulin Pumps, stated that it has learned that UnitedHealthcare yesterday announced that effective July 1, 2016, UnitedHealthcare Community Plan and Commercial members will no longer have an in-network choice among insulin pump providers. This unexpected decision by UnitedHealthcare designates Medtronic as their preferred, in-network durable medical equipment provider of insulin pumps.
#insulin pump
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly adjusted revenues of $3.071 billion for the second fiscal quarter ended March 31, 2016, an increase of 49.7 percent over the prior-year period reported revenues, or 55.2 percent on a currency-neutral basis. On a comparable, currency-neutral basis, second quarter adjusted revenues grew 5.3 percent. As reported, second quarter revenues were $3.067 billion, an increase of 49.6 percent over the prior-year period. The Company's Diabetes Care revenue increased by 4% YoY.
LabStyle Innovations Corp. (NASDAQ: DRIO), developer of the Dario™ Diabetes Management Tool, today announced that it has been granted a key patent by the European Patent Office (EPO) for the company's personalized blood glucose monitoring device. The patent, EP2569622, entitled "FLUID TESTING APPARATUS AND METHODS OF USE," covers claims related to a method and apparatus for performing fluid parameter measurement on a fluid sample via an earphone socket on a mobile phone. The EPO decision to grant was reached on April 7, 2016, and the patent became effective on May 4, 2016.
#bgm
In connection to the upcoming launch of Actiste®, Brighter’s new advisor Jorge C. Otero is an important link to the global pharmaceutical industry. Together with the company's management Jorge C. Otero will develop the go to market strategies for Actiste and evaluate additional business areas in which the product can be applied, in addition to diabetes.